

Press Release

ProStrakan Group plc

BLOCK LISTING SIX MONTHLY RETURN

INFORMATION PROVIDED ON THIS FORM MUST BE TYPED OR PRINTED ELECTRONICALLY AND PROVIDED TO AN *R/S*.

Date: 06.09.2010

Name of <i>applicant</i> :		ProStrakan Group PLC		
Name of scheme:		ProStrakan Group Performance Share Plan 2005		
Period of return:	From:	05.03.2010	To:	04.09.2010
Balance of unallotted securities under scheme(s) from previous return:		2,500,000 ordinary shares of 5p each		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		N/A		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		1,000,000 ordinary shares of 5p each		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		1,500,000 ordinary shares of 5p each		
Name of contact:		Andrew McLean		
Telephone number of contact:		01896 664 096		

For further enquiries, please contact:

ProStrakan	+44 (0) 1896 664000
Callum Spreng, Corporate Communications	
Brunswick Group	+44 (0) 20 7404 5959
Jon Coles / Justine McIlroy	

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

You can learn more about the business at: www.prostrakan.com